Google+

June 15-18, 2015 | Philadelphia, PA

BIO Buzz - Official Show Daily, Brought to you by Alexandria

Health Care

Videos

Trevor Mundel, Gates Foundation at the 2014 BIO International Convention
Brad Zakes, Cerevast Therapeutics at the 2014 BIO International Convention
Jean-Marc Quach, Alpha-1 Project at the 2014 BIO International Convention
Gordon Cadwgan, Alpha-1 Foundation at 2014 BIO International Convention
Alexandria Freitas, National Organization of Rare Disorders at the 2014 BIO International Convention
Ross Sibucao, Hawaii Papaya Industry Association at the 2014 BIO International Convention
Josh Sommer, Chordoma Foundation at the 2014 BIO International Convention
Bahija Jallal, MedImmune at the 2014 BIO International Convention
Deborah Dunsire, FORUM Pharmaceuticals Inc. at the 2014 BIO International Convention
Anne Wojcicki, 23andMe at the 2014 BIO International Convention
Sarkis Mazmanian, Cal Tech at the 2014 BIO International Convention
Private video
Private video
Francis Collins, NIH at 2014 BIO International Convention
Suzanne Ffolkes, Research! America, at the 2014 BIO International Convention
Travis Mickle, KemPharm Inc. at the 2014 BIO International Convention
International BioGENEius Challenge Winner Emily Wang at the 2014 BIO International Convention
Christophe Ramstein, Novasentis exhibiting in the Innovation Zone at BIO 2014

Articles from BioTechNow

Is Regulatory Transformation for Alzheimer’s Therapies Needed?

Publish Date: 7/1/2014, Created By: BIOtechNOW Editor


BIO 2014′s  session titled ” Regulatory Transformation: As Alzheimer’s Disease Science, Research and Advocacy Move Toward Earlier Detection and Intervention, How Will Researchers Adapt to this Evolution?” discussed progress and challenges facing researchers and the collaborative efforts between the Food and Drug Administration (FDA) and patient advocacy groups to help them find a cure. The discussion centered on recent FDA Draft Guidance for Early Stage Alzheimer’s Disease Drug Development which allows for an accelerated approval ...

Read More >

Exchange Plans are Helping Patients, But Challenges Remain

Publish Date: 6/26/2014, Created By: Erin Estey Hertzog


After describing many of the benefits the Exchanges have brought to patients—including access to both coverage and federal subsidies—the moderator for the 2014 BIO International Convention breakout session, Impact of Exchanges for Patients, tasked panelists representing a diverse group of stakeholders to describe the challenges that remain for patients enrolled in Exchange plans. These challenges fell into four main categories, including: formulary depth, patient out-of-pocket costs, transparency, and provider networks. In terms of formulary depth, ...

Read More >

Access to Big Data

Publish Date: 6/26/2014, Created By: BIOtechNOW Editor


Aquiring information rapidly and reliably reduces costs and advances discovery Sixty years ago, when James Watson and Francis Crick elucidated and published their seminal work on the double helical nature of DNA, they could hardly have imagined the explosion of information about cellular activities and disease pathways happening today. With this explosion, the challenge for scientific database producers is to curate and process the published literature, small molecules, proteins, sequences and numeric data in ways ...

Read More >

Seeing is Believing

Publish Date: 6/26/2014, Created By: BIOtechNOW Editor


PET and MRI imaging helps companies to make go/no go decisions earlier Attrition or failure of new drug programs is a major source of concern, with failure rates ranging from 75 percent in anti-infectives to 92 percent in CNS according to DiMasi’s 2010 study (Clin. Pharmacol. Ther. 87, 272-277). Molecular imaging – both Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) can help improve these dismal statistics. Given the immense costs involved in the ...

Read More >

A Better Way to Make Unnatural Amino Acids Discovered by Yu

Publish Date: 6/26/2014, Created By: BIOtechNOW Editor


Certain amino acids that are not found in nature are highly sought after by pharmaceutical manufacturers. These “unnatural” amino acids have traditionally been very difficult to synthesize, so a new and improved technique for doing so is attracting a lot of attention. Amino acids are among the most basic components of living things. Long chains of them, translated from DNA, fold up to become proteins, some smaller groupings of amino acids form hormones, and a ...

Read More >

New Target for Alzheimer’s Disease

Publish Date: 6/26/2014, Created By: BIOtechNOW Editor


Biotechnologists have developed a drug candidate that blocks production of diseasecausing neurotoxins in mouse models Reducing the concentration of cathepsin B using an enzyme inhibitor prevents the creation of the neurotoxic peptide, pyroglutamate-AB (pGlu-AB), which has been linked to the development of Alzheimer’s disease (AD). The candidate inhibitor drug, a cysteine protease inhibitor named E64d, was developed by scientists from the University of California, San Diego School of Medicine, the Medical University of South Carolina and ...

Read More >

Making the Case for Personalized Medicine

Publish Date: 6/26/2014, Created By: BIOtechNOW Editor


Personalized medicine is the customization of healthcare. Already, a suite of molecular approaches is being used to tailor certain medical decisions, practice and products to the individual patient. For example, melanoma, leukemia and metastatic lung, breast and brain cancers can be routinely “molecularly diagnosed” and treated with medicines that target the specific genetic mutations. These represent a remarkable improvement over trial-and-error medicine. Other diagnostic tests use the patient’s DNA sequence to determine drug-metabolizing capabilities. This ...

Read More >

21st Century Cures: Accelerating the Discovery-Development-Delivery Cycle

Publish Date: 6/26/2014, Created By: BIOtechNOW Editor


How can we give patients faster access to innovative treatments and cures? That’s the question the House Energy and Commerce Committee is asking our nation’s foremost medical experts and innovators through white papers, hearings, and roundtables in an initiative we call 21st Century Cures. Our collaboration includes everyone from the National Institutes of Health and the Food and Drug Administration to patients, researchers, health entrepreneurs, and other thought leaders. Through 21st Century Cures, our goal ...

Read More >

NIH, Patients and Industry Ramp Up to AMP-lify Innovation

Publish Date: 6/25/2014, Created By: Tracy Cooley


Speakers at Wednesday’s BIO 2014 Super Session – AMP-lifying Innovation: NIH, Patient Organizations & Leading Biopharma Firms Mobilize to Tackle Tough Diseases – discussed the new Accelerating Medicines Partnership (AMP) program, which is aimed at transforming the current model for developing new treatments by jointly identifying and validating promising biological targets of disease. AMP is a new venture among the NIH, several non-profit organizations and 10 biopharmaceutical companies focused on Alzheimer’s disease; type 2 diabetes ...

Read More >

Digital Health in a Mobile World

Publish Date: 6/25/2014, Created By: BIOtechNOW Editor


Healthcare is shaping up to be an important area for all the big technology companies that focus on mobile devices. And that is pretty much all of them. When Sony sold off its VAIO computer division to Japan Industrial Partners earlier this year, among the reasons given were “drastic changes in the global PC industry”, and a need to “concentrate on … smartphones and tablets.” Over at Microsoft, new CEO Satya Nadella says we’ve entered ...

Read More >

Thank you to our 2014 Sponsors

Double Helix Sponsors

Helix Sponsors

Sponsors